Cargando…

Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients

Hematopoietic stem cell transplant (HSCT) recipients are at high-risk for severe COVID-19 and have altered immune responses to vaccination. We sought to evaluate the dynamics of immune response to BNT162b2 mRNA vaccine in HSCT recipients. We systematically proposed vaccination with BNT162b2 to HSCT...

Descripción completa

Detalles Bibliográficos
Autores principales: Leclerc, Mathieu, Redjoul, Rabah, Le Bouter, Anne, Beckerich, Florence, Robin, Christine, Parinet, Vincent, Pautas, Cécile, Menouche, Dehbia, Bouledroua, Selwa, Roy, Lydia, Cabanne, Ludovic, Nait-Sidenas, Yakout, Fourati, Slim, Maury, Sébastien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931584/
https://www.ncbi.nlm.nih.gov/pubmed/35303906
http://dx.doi.org/10.1186/s13045-022-01250-2
_version_ 1784671296750092288
author Leclerc, Mathieu
Redjoul, Rabah
Le Bouter, Anne
Beckerich, Florence
Robin, Christine
Parinet, Vincent
Pautas, Cécile
Menouche, Dehbia
Bouledroua, Selwa
Roy, Lydia
Cabanne, Ludovic
Nait-Sidenas, Yakout
Fourati, Slim
Maury, Sébastien
author_facet Leclerc, Mathieu
Redjoul, Rabah
Le Bouter, Anne
Beckerich, Florence
Robin, Christine
Parinet, Vincent
Pautas, Cécile
Menouche, Dehbia
Bouledroua, Selwa
Roy, Lydia
Cabanne, Ludovic
Nait-Sidenas, Yakout
Fourati, Slim
Maury, Sébastien
author_sort Leclerc, Mathieu
collection PubMed
description Hematopoietic stem cell transplant (HSCT) recipients are at high-risk for severe COVID-19 and have altered immune responses to vaccination. We sought to evaluate the dynamics of immune response to BNT162b2 mRNA vaccine in HSCT recipients. We systematically proposed vaccination with BNT162b2 to HSCT recipients and gave a third vaccine dose to those showing titers of IgG(S-RBD) below 4160 AU/mL 1 month following the second dose. We then quantified anti-SARS-CoV-2 antibodies dynamics in 133 of these HSCT recipients (88 after two and 45 after three vaccine doses) 6 months after the first vaccine dose. Mean IgG(S-RBD) titer at 6 months was significantly lower than the peak value measured 1 month after a second (p < 0.001) or third (p < 0.01) vaccine dose. IgG(S-RBD) titers at 6 months were strongly correlated to peak values (p < 0.001) and a peak titer above 10,370 AU/mL predicted persistent protection at 6 months. Seventy-two percent (96/133) of patients retained protective antibody levels at 6 months. Immunosuppressive drugs and low lymphocyte counts in peripheral blood correlated with lower IgG(S-RBD) titers at 6 months. Four patients (3%) developed PCR-documented SARS-CoV-2 infection and one died. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13045-022-01250-2.
format Online
Article
Text
id pubmed-8931584
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89315842022-03-18 Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients Leclerc, Mathieu Redjoul, Rabah Le Bouter, Anne Beckerich, Florence Robin, Christine Parinet, Vincent Pautas, Cécile Menouche, Dehbia Bouledroua, Selwa Roy, Lydia Cabanne, Ludovic Nait-Sidenas, Yakout Fourati, Slim Maury, Sébastien J Hematol Oncol Rapid Communication Hematopoietic stem cell transplant (HSCT) recipients are at high-risk for severe COVID-19 and have altered immune responses to vaccination. We sought to evaluate the dynamics of immune response to BNT162b2 mRNA vaccine in HSCT recipients. We systematically proposed vaccination with BNT162b2 to HSCT recipients and gave a third vaccine dose to those showing titers of IgG(S-RBD) below 4160 AU/mL 1 month following the second dose. We then quantified anti-SARS-CoV-2 antibodies dynamics in 133 of these HSCT recipients (88 after two and 45 after three vaccine doses) 6 months after the first vaccine dose. Mean IgG(S-RBD) titer at 6 months was significantly lower than the peak value measured 1 month after a second (p < 0.001) or third (p < 0.01) vaccine dose. IgG(S-RBD) titers at 6 months were strongly correlated to peak values (p < 0.001) and a peak titer above 10,370 AU/mL predicted persistent protection at 6 months. Seventy-two percent (96/133) of patients retained protective antibody levels at 6 months. Immunosuppressive drugs and low lymphocyte counts in peripheral blood correlated with lower IgG(S-RBD) titers at 6 months. Four patients (3%) developed PCR-documented SARS-CoV-2 infection and one died. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13045-022-01250-2. BioMed Central 2022-03-18 /pmc/articles/PMC8931584/ /pubmed/35303906 http://dx.doi.org/10.1186/s13045-022-01250-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Rapid Communication
Leclerc, Mathieu
Redjoul, Rabah
Le Bouter, Anne
Beckerich, Florence
Robin, Christine
Parinet, Vincent
Pautas, Cécile
Menouche, Dehbia
Bouledroua, Selwa
Roy, Lydia
Cabanne, Ludovic
Nait-Sidenas, Yakout
Fourati, Slim
Maury, Sébastien
Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients
title Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients
title_full Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients
title_fullStr Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients
title_full_unstemmed Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients
title_short Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients
title_sort determinants of sars-cov-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931584/
https://www.ncbi.nlm.nih.gov/pubmed/35303906
http://dx.doi.org/10.1186/s13045-022-01250-2
work_keys_str_mv AT leclercmathieu determinantsofsarscov2waningimmunityinallogeneichematopoieticstemcelltransplantrecipients
AT redjoulrabah determinantsofsarscov2waningimmunityinallogeneichematopoieticstemcelltransplantrecipients
AT lebouteranne determinantsofsarscov2waningimmunityinallogeneichematopoieticstemcelltransplantrecipients
AT beckerichflorence determinantsofsarscov2waningimmunityinallogeneichematopoieticstemcelltransplantrecipients
AT robinchristine determinantsofsarscov2waningimmunityinallogeneichematopoieticstemcelltransplantrecipients
AT parinetvincent determinantsofsarscov2waningimmunityinallogeneichematopoieticstemcelltransplantrecipients
AT pautascecile determinantsofsarscov2waningimmunityinallogeneichematopoieticstemcelltransplantrecipients
AT menouchedehbia determinantsofsarscov2waningimmunityinallogeneichematopoieticstemcelltransplantrecipients
AT bouledrouaselwa determinantsofsarscov2waningimmunityinallogeneichematopoieticstemcelltransplantrecipients
AT roylydia determinantsofsarscov2waningimmunityinallogeneichematopoieticstemcelltransplantrecipients
AT cabanneludovic determinantsofsarscov2waningimmunityinallogeneichematopoieticstemcelltransplantrecipients
AT naitsidenasyakout determinantsofsarscov2waningimmunityinallogeneichematopoieticstemcelltransplantrecipients
AT fouratislim determinantsofsarscov2waningimmunityinallogeneichematopoieticstemcelltransplantrecipients
AT maurysebastien determinantsofsarscov2waningimmunityinallogeneichematopoieticstemcelltransplantrecipients